MarketPulse

biosimilars

12 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Amgen and Merck Emerge as Defensive Dividend Plays Amid Economic Uncertainty

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.
AMGNMRKbiotechpharmaceuticals
BenzingaBenzinga··Nabaparna Bhattacharya

Amneal Pharmaceuticals Surges on $1.1B Kashiv Acquisition to Dominate Biosimilars

Amneal Pharmaceuticals surged 3.76% after agreeing to acquire Kashiv BioSciences for $1.1 billion, positioning itself in the $300 billion biosimilars market.
AMRXXPHASCEacquisitionstrategic partnership
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

SLE Drug Market to Nearly Triple to $5.9B by 2034 as New Therapies Challenge Generics

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.
BMYCELGrABBVNVSRHHBY+3market forecastbiosimilars
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Crohn's Disease Drug Market Set to Expand 45% by 2032 Amid Novel Treatment Wave

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.
JNJMRKPFEABBVLLY+6market growthbiosimilars
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Avastin Market Poised for 45% Growth Through 2030 as Biosimilars Expand Access

Avastin market projected to grow from $7.82B in 2025 to $11.27B by 2030 at 7.5% CAGR, driven by cancer prevalence and biosimilar expansion.
RHHBYcolorectal cancercancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Alvotech Expands Pipeline With 9 Biosimilar Candidates in Development

Alvotech files 2025 annual report with SEC, reporting five marketed biosimilars and nine additional candidates in development across therapeutic areas.
ALVOALVOWregulatory complianceForm 20-F
GlobeNewswire Inc.GlobeNewswire Inc.··Alvotech

Alvotech Files 2025 Annual Report, Providing Full Financial Disclosure to US Investors

Alvotech files 2025 Annual Report on Form 20-F with SEC, providing comprehensive financial disclosures to U.S. investors via SEC Edgar and company website.
ALVOALVOWbiotechForm 20-F
GlobeNewswire Inc.GlobeNewswire Inc.··Alvotech

Alvotech Advances Biosimilar Pipeline With Five Marketed Products, Nine In Development

Alvotech files 2025 annual SEC report with five marketed biosimilars and nine pipeline candidates supported by global partnerships.
ALVOALVOWForm 20-FSEC filing
GlobeNewswire Inc.GlobeNewswire Inc.··Alvotech

Alvotech Expands Biosimilar Pipeline With Five Approved Drugs, Nine in Development

Alvotech files 2025 annual report showing five approved biosimilars and nine pipeline candidates across multiple therapeutic areas, positioning the company amid rapid biosimilar market growth.
ALVOALVOWregulatory complianceForm 20-F
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Bet on Organon Stock Signals Turnaround Faith Despite 61% Collapse

Sio Capital Management invested $24.53 million in Organon ($OGN) at $6.03/share, betting on turnaround potential despite 61% annual decline. Company maintains flat 2026 guidance with $1.9B adjusted EBITDA.
OGNvalue investinginstitutional investment
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Neumega Poised for Robust Growth Through 2030 as Oncology Demand Surges

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.
PFEpersonalized medicineAsia Pacific growth
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Biopharmaceutical CMO Market Set to Quadruple to $76.2B by 2035

Biopharmaceutical CMO market to grow from $21.16B in 2025 to $76.2B by 2035, driven by outsourcing demand and capacity constraints.
TMOLZAGYWXXWYbiologicsmonoclonal antibodies